Compositions for activating pyruvate kinase
US-10208052-B1 · Feb 19, 2019 · US
Compositions for activating pyruvate kinase
US10472371B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10472371-B2 |
| Application number | US-201916245654-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2019 |
| Priority date | Mar 20, 2017 |
| Publication date | Nov 12, 2019 |
| Grant date | Nov 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
First claim
Opening claim text (preview).
We claim: 1. A composition comprising compound 2: 2. A composition comprising compound 3: 3. A composition comprising compound 4:
Assignees
Inventors
Classifications
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
- A61K31/407Primary
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title
- A61K31/047Primary
having two or more hydroxy groups, e.g. sorbitol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10472371B2 cover?
- Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
- Who is the assignee on this patent?
- Forma Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).